RE:RE:RE:RE:RE:RE:RE:RE:News from Taurx Indeed. There is a lot of discussion about TauRx on i3 forum as it relates to Genting's recent rally.
https://klse.i3investor.com/web/forum/forum-thread/800000520
Some suggesting that Taurx shares have recently traded at the US$200 - US$250 price. I'm not sure I believe that. Dundee carrying TauRx at US$48 at June 30, 2023. So a TauRx price anywhere near that level would value Dundee's Taurx investment way over its current market cap (I believe Dundee has just over 1 million TauRx shares).
Here are a few intresting comments from the Forum related to Taurx and Genting's recent share price run....
"
@Havefun It's traded privately, current price is around 200-250 USD. Most likely looking for trade sale of the company, unlikely to be IPO."
"Good sign. 3 months ago Taurx shares still at usd150 each, now usd200 each and a lot of buyers. FDA grants AA to a neuro drug recently based on their NfL data as biomarker. Our NfL data is even stronger than Torfersen's. That is why this new NfL data is very important for Taurx. Read this news carefully: https://finance.yahoo.com/news/fda-grants-accelerated-approval-qalsody-190400118.html"
"
https://ams3.digitaloceanspaces.com/taurx/pdfs/AAIC_NfL-Oral-Presentation-Press-Release_16Jul2023.FINAL.pdf https://finance.yahoo.com/news/fda-grants-accelerated-approval-qalsody-190400118.html Justborn ah, latest news la. 55% reduction in NfL has already secured FDA approval. You think HMTM's 93% reduction in NfL can get FDA approval or not lah?" "
Of course good news la. HMTM's FDA AA almost a certainty (see my posted link on Tofersen's FDA AA based on their much weaker NfL data). HMTM's NfL data just released today afternoon still fresh from oven."